
Safety Profile of CT1812 and Its Effect on Proteomic Biomarkers of Alzheimer Disease: Mary Hamby, PhD
WATCH TIME: 3 minutes "We identified key pharmacodynamic biomarkers of CT1812 that correlate with reduced neurodegeneration and improved cognitive outcomes. This builds out our biomarker program, helping us understand the biological impact of CT1812 …